Ropivacaine in the horse: Its pharmacological responses, urinary detection and mass spectral confirmation

J. D. Harkins, W. Karpiesiuk, A. Lehner, W. E. Woods, L. Dirikolu, W. G. Carter, J. Boyles, T. Tobin

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

This report evaluates the pharmacological responses, urinary detection and mass spectral confirmation of ropivacaine in horses. Ropivacaine, a potent local anesthetic (LA) recently introduced in human medicine, has an estimated highest no-effect close (HNED) of about 0.4 mg/site as determined in our abaxial sesamoid block model. Apparent ropivacaine equivalents were detectable by ELISA screening using a mepivacaine ELISA test after administration of clinically effective doses. Mass spectral examination of postadministration urine samples showed no detectable parent ropivacaine, but a compound indistinguishable from authentic 3-hydroxyropivacaine was recovered from these samples. The study shows that ropivacaine is a potent LA in the horse, that clinically effective doses can be detected in postadministration samples by ELISA-based screening, and that its major post administration urinary metabolite is 3-hydroxyropivacaine.

Original languageEnglish
Pages (from-to)89-98
Number of pages10
JournalJournal of Veterinary Pharmacology and Therapeutics
Volume24
Issue number2
DOIs
StatePublished - 2001

ASJC Scopus subject areas

  • Pharmacology
  • General Veterinary

Fingerprint

Dive into the research topics of 'Ropivacaine in the horse: Its pharmacological responses, urinary detection and mass spectral confirmation'. Together they form a unique fingerprint.

Cite this